Jeffrey Anderson was appointed our President in March 2019. Prior to that he served as our Senior Vice President of Clinical and Regulatory affairs since December 2013, overseeing all aspects of the clinical evaluation and regulatory approval of the Company’s products as well as the commercial launch in several key markets. Previously, he served as our Vice President of Clinical and Regulatory affairs from 2004 to 2008, and again from February 2011 until his promotion to Senior Vice President. He has over 25 years of experience in the medical device industry, including his positions of Vice President of Clinical & Regulatory Affairs and Vice President of Research & Development for Neomend, a biomedical device company engaged in the development and commercialization of surgical wound healing products, where he served from October 2008 through February 2011. Additionally, Mr. Anderson has held senior positions at Abbott Vascular, Jomed, CRS Clinical Research, and Medtronic. He received his B.S. in Physics from California State University at Fullerton.
Jessica Earley was appointed our Vice President of Operations and Product Development in January 2019. She has been with REVA since 2003 and directed the scaffold development program since 2015 and operations since 2016. In her 18 years of industry experience, she has held engineering, program management and operational management positions in the pharmaceutical and medical device industries. Jessica holds a Chemical Engineering degree from the University of New Hampshire.
Sue Poinsett was appointed our Director of Quality Assurance and Regulatory Affairs in March 2018. Previous to this role, she served as our Director of Quality since October 2014. Sue has over 25 years of experience in Quality and Regulatory leadership positions in the medical device and pharmaceutical industries, including ZELTIQ Aesthetics (now Allergan), Sherpa Clinical, and Wesley Jessen. She earned her bachelor’s of science degree in Microbiology and her master’s of science degree in Food Biotechnology, both from the University of Minnesota.
Erik Wiberg was appointed our Chief Financial Officer on March 2, 2020. He has over 25 years of operating finance and M&A experience. Most recently Erik was CFO of Gyros Protein Technologies which was bought by Mesa Labs in Q4 2019. Earlier in his career Erik held various finance leadership positions at ThermoFisher and Honeywell. Erik has an M.B.A. degree from the Anderson Graduate School of Management at U.C. Los Angeles and a B.S. degree in Mechanical Engineering from U.C. San Diego.